Obesity and Early Biologic Failure in Psoriasis: An Italian Multicentre Retrospective Cohort Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Obesity and Early Biologic Treatment Failure in Psoriasis: A Retrospective Cohort Study Across Italian Centers

  • By

  • Jacopo Tartaglia

  • Massimo Donini

  • Carlo Garbo

  • Alessandro Gatti

  • Paolo Gisondi

  • Niccolò Romagnolo

  • Lorenzo Schiesari

  • Stefano Piaserico

  • October 13, 2026

Share

  • 1

    This retrospective study analyzed biologic treatment lines among adults with plaque psoriasis treated at five dermatology centers in Italy’s Veneto region.

  • 2

    Primary failure occurred in 17.0% of treatment lines among patients with obesity and 5.8% among those without obesity.

  • 3

    After multivariable adjustment, obesity was associated with primary biologic failure (HR, 2.75; 95% CI, 1.59-4.77).

  • 4

    Higher BMI was associated with increased primary failure risk, while obesity was not significantly associated with secondary failure or safety-related discontinuation.

  • 5

    Among patients with obesity, TNF-α inhibitors had the highest primary failure rate, and IL-17 and IL-23 pathway inhibitors had lower adjusted risks than TNF-α inhibitors.

Original Source(s)

Obesity and Early Biologic Failure in Psoriasis: An Italian Multicentre Retrospective Cohort Study

  • by Jacopo Tartaglia, Massimo Donini, Carlo Garbo, Alessandro Gatti, Paolo Gisondi, Niccolò Romagnolo, Lorenzo Schiesari, Stefano Piaserico

  • October 13, 2026

Related Content

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”